- Patent Title: HGF preparation suitable for treatment of neurological disorders
-
Application No.: US16235132Application Date: 2018-12-28
-
Publication No.: US10702582B2Publication Date: 2020-07-07
- Inventor: Kazuhiro Fukuta , Hayao Inoue
- Applicant: KRINGLE PHARMA INC.
- Applicant Address: JP Osaka
- Assignee: KRINGLE PHARMA INC.
- Current Assignee: KRINGLE PHARMA INC.
- Current Assignee Address: JP Osaka
- Agency: Wenderoth, Lind & Ponack, L.L.P.
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@51a207a0
- Main IPC: A61K38/18
- IPC: A61K38/18 ; A61K38/22 ; A61K47/02 ; A61K47/12 ; A61K47/26 ; A61K9/08 ; A61K9/19 ; A61P9/10 ; A61P25/16 ; A61P25/14 ; A61P25/28 ; A61K9/00 ; A61K47/18

Abstract:
The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.
Public/Granted literature
- US20190117732A1 HGF PREPARATION SUITABLE FOR TREATMENT OF NEUROLOGICAL DISORDERS Public/Granted day:2019-04-25
Information query
IPC分类: